Sonic Fund II, L.P., Sonic GP LLC, and Lawrence Kam filed Amendment No. 4 to their Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of common shares in Fennec Pharmaceuticals Inc. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: The three reporting persons collectively may be deemed to beneficially own 1,592,559 shares of Fennec Pharmaceuticals common stock, no par value.
- Percent of class: Lawrence Kam's aggregate holdings represent 4.5% of the class, based on 35,305,117 shares outstanding as of November 10, 2026.
- Fund-level stake: Sonic Fund II, L.P. and Sonic GP LLC each report shared voting and dispositive power over 1,457,357 shares, representing 4.1% of the class.
- Kam's direct holdings: Lawrence Kam holds sole voting and dispositive power over 135,202 shares in addition to his shared interest in the Fund's shares.
- Ownership threshold: The filing was made under Item 5, which the filing identifies as ownership of 5 percent or less of a class.
- Shares outstanding source: The 35,305,117 figure was drawn from Fennec Pharmaceuticals' Quarterly Report filed with the SEC on November 12, 2026.
Lawrence Kam and Sonic Fund II Disclose Fennec Pharmaceuticals Position
According to the filing, Sonic Fund II, L.P. holds the shares directly. Sonic GP LLC, as the general partner of the Fund, may be deemed to beneficially own the same shares by virtue of that relationship. Lawrence Kam, as the managing member of Sonic GP LLC, may in turn be deemed to beneficially own the shares attributable to the General Partner. Fennec Pharmaceuticals Inc., the issuer, is a pharmaceutical company headquartered at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709, and its common stock carries no par value under CUSIP number 31447P100.
The filing reports that neither Sonic Fund II, L.P. nor Sonic GP LLC hold any sole voting or dispositive power; all 1,457,357 shares attributed to those two entities are classified as shared. Kam personally holds an additional 135,202 shares over which he exercises sole voting and dispositive power, bringing his total beneficial ownership to 1,592,559 shares, or 4.5% of the class. The reporting persons are organized in Delaware, with principal offices at 400 Hobron Lane, Suite 3709, Honolulu, HI 96815. The filing is listed on NASDAQ:FENC.
The certifications included in the filing state that, to the best of the signatories' knowledge and belief, the securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Section 240.14a-11.
What Was Disclosed
Three reporting persons, Sonic Fund II, L.P., Sonic GP LLC, and Lawrence Kam, filed Amendment No. 4 to a Schedule 13G disclosing aggregate beneficial ownership of 1,592,559 Fennec Pharmaceuticals common shares, equal to 4.5% of the class, as of September 30, 2026.



Please wait processing your request...